Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
As an increasing number of cell and gene therapies are US Food and Drug Administration approved, health care stakeholders are attempting to strike a balance between patient access to innovative treatments and overall affordability. Read about the survey by Precision's Erin Lopata, Christopher Terrone and Ami Gopalan to understand how access decision-makers and employers are using innovative financial models to support coverage of high-investment medications.
The Inflation Reduction Act will shift formulary development and contracting dynamics. Time for manufacturers to have a clear, persuasive value story. Learn more from PRECISIONvalue expert Erin Lopata.
Patients already look beyond their prescription benefits for ways to pay. The Inflation Reduction Act is likely to increase demand for new solutions. PRECISIONvalue Chief Medical Officer Dominic Galante explains why.
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer explains the anticipated fallout from the Inflation Reduction Act in this free report.
The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.
Biosimilars are on track to reduce drug costs by $100 billion—but not everyone is on board. The Inflation Reduction Act has provisions that encourage their uptake. Get the details from PRECISIONvalue expert Amy Martin in this free brief (part 1 of 5).
The March Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
To be prepared for the next pandemic, we must consider what went wrong with the COVID-19 pandemic and what went right. From telemedicine services to licensure requirements, what does the health care community still need to do to prepare? Precision's Maureen Hennessey and Cynthia Miller discuss what infection prevention and control personnel need to know to prepare for future epidemics and pandemics. Installment 3 of 3.
The media regularly covers the number of cases in the triple epidemic or “tripledemic” of influenza, COVID-19, and respiratory syncytial virus. Precision's Maureen Hennessey and Cynthia Miller argue the media should cover more expansive topics beyond the number of cases, and explain why advocacy groups are needed to assist patients dealing with COVID-19, long COVID, and the aftermath.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
